Neural Regeneration Research ›› 2012, Vol. 7 ›› Issue (9): 708-713.

Previous Articles     Next Articles

Recombinant adeno-associated virus delivered human thioredoxin-PR39 prevents hypoxia-induced apoptosis of ECV304 cells

Xiyun Ruan1, Zhenguo Yuan2, Yifeng Du1, Guangxiao Yang3, Quanying Wang3   

  1. 1 Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong Province, China
    2 Shandong Medical Imaging Research Institute, Affiliated to Shandong University, Jinan 250021, Shandong Province, China
    3 Xi’an Huaguang Biological Engineering Co., Ltd., Xi'an 710025, Shaanxi Province, China
  • Received:2011-11-09 Revised:2012-01-14 Online:2012-03-25 Published:2012-03-25
  • Contact: Zhenguo Yuan, M.D., Associate chief physician, Shandong Medical Imaging Research Institute, Affiliated to Shandong University, Jinan 250021, Shandong Province, China yuanzhenguo@hotmail.com
  • About author:Xiyun Ruan☆, M.D., Associate chief physician, Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong Province, China

PDF

907

Abstract:

Human thioredoxin and antibacterial peptide, PR39, have been shown to have potent antioxidant effects that may prolong survival of cells during hypoxia. The pSSCMV/human thioredoxin-PR39 vector was successfully constructed in this study and used to infect ECV304 cells. Transfected ECV304 cells were incubated at 1%, 5% hypoxic, and normal oxygen conditions. We found that the number of apoptotic cells after transfection with recombinant adeno-associated virus-human thioredoxin -PR39 was significantly lower than controls, suggesting a protective effect of the recombinant human thioredoxin-PR39 protein on hypoxic cells.

Key words: human thioredoxin, antimicrobial peptide PR39, fusion gene, recombinant adeno-associated virus, gene therapy, apoptosis, hypoxia